Videos | Cardiovascular Ultrasound

This is an example of an augmented reality (AR) training system for transesophageal echo (TEE) created by the simulation ...

Home December 19, 2019
Home
News | Cardiac Diagnostics

December 19, 2019 — The U.S. Food and Drug Administration (FDA) has granted breakthrough status for a novel ECG-based ...

Home December 19, 2019
Home
Videos | RSNA

DAIC Editor Dave Fornell and Imaging Technology News (ITN) Consulting Editor Greg Freiherr offer a post-game report on ...

Home December 18, 2019
Home
News | Cardiac Diagnostics

December 18, 2019 — In their latest report, “Cardiovascular Disease 2020-2030: Trends, Technologies & Outlook” IDTechEx ...

Home December 18, 2019
Home
News | Left Atrial Appendage (LAA) Occluders

December 18, 2019 — Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke ...

Home December 18, 2019
Home
News | Heart Failure

December 18, 2019 — BioVentrix, Inc., developer of the first less invasive system for left ventricular remodeling, today ...

Home December 18, 2019
Home
News | Cath Lab

December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S. Food ...

Home December 18, 2019
Home
The most popular content in the month of November on DAIC was by far the data from the late-breaking trials from the American Herart Association (AHA) 2019 meeting. The second item on this month's list is an overview of key heart failure takeaways from AHA by Nasrien Ibrahim, M.D., associate director of resynchronization and advanced cardiac therapeutics at Massachusetts General Hospital.  Photo by Scott Morgan/AHA.
Feature

December 16, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home December 17, 2019
Home
Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals | Dave Fornell, Editor

The U.S. Food and Drug Administration (FDA) approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels

Home December 16, 2019
Home
News | Heart Failure

December 12, 2019 — Impulse Dynamics, developer of Optimizer Smart System for delivering CCM therapy, announced the ...

Home December 12, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African ...

Home December 12, 2019
Home
News | ECG

December 12, 2019 — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, announced today ...

Home December 12, 2019
Home
News | Cardiac Imaging

December 9, 2019 — DiA Imaging Analysis Ltd., an IBM Alpha Zone Accelerator Alumni Startup, announces a collaboration ...

Home December 09, 2019
Home
News | Virtual and Augmented Reality

November 27, 2019 — CAE Healthcare will showcase its mixed reality training solutions for practicing physicians and ...

Home November 27, 2019
Home
A sample of the transcatheter mitral valve replacement (TMVR) devices in development or clinical trials.
Feature | Heart Valve Technology | Saipriya Iyer

The overwhelming success story for transcatheter aortic valve replacement (TAVR) moving from a science project to ...

Home November 27, 2019
Home
Subscribe Now